Could a daily pill prevent dialysis catheter failures?

NCT ID NCT07404345

Not yet recruiting Disease control Sponsor: Hospital Civil de Guadalajara Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding a low-dose blood thinner (apixaban) to the standard heparin lock can help dialysis catheters stay functional longer. Fifty-four adults with end-stage kidney disease and a new catheter will be followed for up to 24 months. The goal is to see if this combination reduces the need for emergency treatments or catheter replacement.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Apixaban (a blood thinner) and heparin (a standard catheter lock solution)
What this could lead to: If it works, this could reduce the need for emergency procedures or catheter replacements in dialysis patients, making treatment smoother.
What could go wrong: This is a small, early-phase trial (54 people) at a single center. The blood thinner may increase bleeding risk, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMODIALYSIS ACCESS FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease end stage renal failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMODIALYSIS ACCESS FAILURE HEMODIALYSIS CATHETER KIDNEY DISEASE, END-STAGE

Contacts and locations

Locations

Antiguo Hospital Civil de Guadalajara "Fray Antonio Alcalde"

Guadalajara, Jalisco, 44200, Mexico

More trials for these conditions

Other studies related to the condition(s) this trial covers.